Internal mammary node status: A major prognosticator in axillary node-negative breast cancer

1995 ◽  
Vol 2 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Hiram S. Cody ◽  
Jerome A. Urban
Keyword(s):  
Breast Cancer ◽  
Axillary Node ◽  
Internal Mammary Node ◽  
Node Negative ◽  
Node Status ◽  
Node Negative Breast Cancer ◽  
Internal Mammary

Do Internal Mammary Chain Nodes Matter in the Prognosis of Axillary Node-negative Breast Cancer?

2000 ◽  
Vol 39 (3) ◽  
pp. 307-307 ◽  
Author(s):  
Rodrigo Arriagada ◽  
Jean-Marc Guinebretière ◽  
Monique G. Lê
Keyword(s):  
Breast Cancer ◽  
Axillary Node ◽  
Internal Mammary Chain ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Internal Mammary

scholarly journals Tumor-Biological Factors Upa and PAI-1 as Stratification Criteria of a Multicenter Adjuvant Chemotherapy Trial in Node-Negative Breast Cancer

2000 ◽  
Vol 15 (1) ◽  
pp. 73-78 ◽  
Author(s):  
A. Prechtl ◽  
N. Harbeck ◽  
C. Thomssen ◽  
C. Meisner ◽  
M. Braun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Systemic Therapy ◽  
Axillary Node ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Pai 1

In axillary node-negative primary breast cancer, 70% of the patients will be cured by locoregional treatment alone. Therefore, adjuvant systemic therapy is only needed for those 30% of node-negative patients who will relapse after primary therapy and eventually die of metastases. Traditional histomorphological and clinical factors do not provide sufficient information to allow accurate risk group assessment in order to identify node-negative patients who might benefit from adjuvant systemic therapy. In the last decade various groups have reported a strong and statistically independent prognostic impact of the serine protease uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 (plasminogen activator inhibitor type 1) in node-negative breast cancer patients. Based on these data, a prospective multicenter therapy trial in node-negative breast cancer patients was started in Germany in June 1993, supported by the German Research Association (DFG). Axillary node-negative breast cancer patients with high levels of either or both proteolytic factors in the tumor tissue were randomized to adjuvant CMF chemotherapy versus observation only. Recruitment was continued until the end of 1998, by which time 684 patients had been enrolled. Since then, patients have been followed up in order to assess the value of uPA and PAI-1 determination as an adequate selection criterion for adjuvant chemotherapy in node-negative breast cancer patients. This paper reports on the rationale and design of this prospective multicenter clinical trial, which may have an impact on future policies in prognosis-oriented treatment strategies.

scholarly journals Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

BMC Cancer ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Catherine L. Forse ◽  
Seema Agarwal ◽  
Dushanthi Pinnaduwage ◽  
Frank Gertler ◽  
John S. Condeelis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Quantitative Method ◽  
Axillary Node ◽  
Node Negative ◽  
Node Negative Breast Cancer

How To Use Prognostic Factors in Axillary Node-Negative Breast Cancer Patients

1990 ◽  
Vol 82 (12) ◽  
pp. 1006-1015 ◽  
Author(s):  
William L. McGuire ◽  
Atul K. Tandon ◽  
D. Craig Allred ◽  
Gary C. Chamness ◽  
Gary M. Clark
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Axillary Node ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer

Prognosticators in axillary node negative breast cancer

1998 ◽  
Vol 34 ◽  
pp. S106
Author(s):  
W.E. Fiets ◽  
M.A. Blankenstein ◽  
J.W.R. Nortier ◽  
H.M. Rultenberg ◽  
D.H. Rutgers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Axillary Node ◽  
Node Negative ◽  
Node Negative Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document